Platelets pull: how thrombin drives contractility Authors: Molly Y Mollica Published: 2026 In this issue of Blood Advances, Hiebner et al1 report that thrombin stimulation boosts single-platelet contractility by 50% compared to stimulation with other agonists. Additionally, the authors show that high thrombin concentrations can overcome the inhibition of clot contraction by antiplatelet drugs. Platelets contract, generating forces that stabilize a primary hemostatic plug and compact a fibrin clot. Prior work has demonstrated that impaired platelet contractility is associated with hemostatic dysfunction, including increased bleeding symptoms,2 thrombus embolization,3 and need for transfusion in trauma victims.4 Platelet contractility can be measured on the multicellular scale with clot retraction and on the single-platelet scale with traction force microscopy. Hiebner et al combined single- and multiplatelet contractility methodologies and complementary biochemical techniques to investigate how agonists present across a thrombus drive platelet contraction. The authors found that single human platelets in the presence of 1 U/mL thrombin generated significantly higher total force and force per area after 1 hour than platelets in the presence of 5 μM ADP or 5 μg/mL collagen-related peptide. Additionally, thrombin stimulation resulted in enhanced phosphorylation of Rho-associated protein kinase (ROCK) 2 and myosin light chain (MYL) 9, increased total protein levels of MYL9 and MYL kinase, and enhanced mRNA levels of ROCK 1, suggesting a mechanism for enhanced platelet contractility with thrombin stimulation. Antiplatelet drugs impaired single-platelet forces and platelet-driven clot contraction, but a high concentration (1 U/mL) of thrombin reversed the impairment of clot contraction. These findings are significant because they characterize single-platelet contractility in response to distinct agonists for the first time, identify thrombin as an agonist that boosts single-platelet forces, and describe a mechanism through which thrombin enhances platelet contractility. Moreover, the findings inform how platelets may contract differently if localized in the thrombin-rich thrombus core compared to the shell. Demonstration that platelet contraction can overcome antiplatelet drugs with enough thrombin has potential implications for the development and administration of drugs to prevent thrombosis without inducing bleeding. For example, this finding may inform risks and mechanisms of combining antiplatelet and anticoagulant drugs. Additionally, it may have implications in reversing dual antiplatelet therapy in patients who are bleeding or who need urgent surgery. Furthermore, although the role of platelet contractility is less well-understood in thrombosis than in bleeding, these results also have potential implications for addressing adverse cardiovascular events that occur despite dual antiplatelet therapy (termed “antiplatelet drug resistance”). A major strength of Hiebner et al’s methodologies is the large quantity of single platelets measured across conditions. Building on the pioneering approaches that first quantified single-platelet contractility ∼15 years ago,5,6 this work seeded washed platelets onto fibrinogen-coated polydimethylsiloxane posts, visualized platelet-induced post deflection with fluorescence microscopy, and calculated single-platelet tractions from post deflections. The findings in this work were enabled by measuring >3000 single platelets across >15 conditions. The ability to measure this quantity of platelet tractions is a testament to recent methodological advances by the authors and others; 15 years ago, single-platelet contractility methodologies were capable of as few as 1 to 4 platelets per subject5 and 14 platelets per study,6 but it has become possible to measure >100 platelets per subject or condition and/or >1000 platelets per study.1,2,7 In addition to advancing the quantity of cells measurable, major recent technological developments in platelet traction force microscopy include enhancing measurement resolution and compatibility with high-resolution immunofluorescence imaging.8,9 Although single-platelet force methodologies have advanced considerably in yield, resolution, and compatibility with measurements of cellular structure, there remains room for improvement to support investigation of unanswered questions. The quantity of platelets and conditions included in Hiebner et al represent some of the best in the field to date, yet the results largely represent platelet contractility in the presence of a single agonist concentration, a single protein treatment, and a single substrate stiffness at a single time point. Further enhancing the multiplexing capabilities of these measurements would enable future studies to reveal a more complete picture of potentially interdependent factors that drive platelet contractility across a thrombus. Single-platelet contractility measurements have advantages such as delivering information on highly heterogeneous platelet populations, visualization of subcellular structure, and potentially enhanced sensitivity compared to clot retraction.10 Nonetheless, open questions exist about how differently platelets may behave (ie, spread, contract) in single-platelet assays compared to in vivo. Enhancing how single-platelet methodologies mimic biology and/or reducing how methodologies inadvertently impact platelet function would enable better understanding of physiologically relevant platelet contractility and the factors that drive it. Taken together, Hiebner et al establish thrombin as a potent driver of platelet contractility and inform how and why platelet contraction may vary across a thrombus. By pairing traction force microscopy methodologies with clot retraction and complementary biochemical techniques, the authors advance understanding of the regulation of platelet contractility and the ability of thrombin to override antiplatelet inhibition. This work is enabled by transformative advances in platelet traction force microscopy over the last 15 years and highlights the future technological developments needed to fully understand the chemical and mechanical cues that drive platelet contractility across a thrombus. Conflict-of-interest disclosure: The author declares no competing financial interests. References